Characterization of Adipose Derived Regenerative Cells (ADRCs) From Patients With Chronic Heart Disease
Characterization of Adipose Derived Regenerative Cells (ADRCs) From Excess Tissue and Cells Designated for Discard From Patients With Chronic Heart Disease
Sponsor: Cytori Therapeutics
This observational or N/A phase trial investigates Chronic Heart Failure and is currently ongoing. Cytori Therapeutics leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Oct 2019 — Jan 2021 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cytori Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .